Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0042109 (urticaria)
 6,569 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Chronic urticaria is highly prevalent in the general population, and while there are multiple treatments for the disorder, the results obtained are not completely satisfactory. The second-generation H1 antihistamines remain the symptomatic treatment option of choice. Depending on the different pharmacokinetics and H1 receptor affinity of each drug substance, different concentrations in skin can be expected, together with different efficacy in relation to the histamine-induced wheal inhibition test--though this does not necessarily have repercussions upon clinical response. The antiinflammatory properties of the H1 antihistamines could be of relevance in chronic urticaria, though it is not clear to what degree they influence the final therapeutic result. Before moving on to another therapeutic level, the advisability of antihistamine dose escalation should be considered, involving increments even above those approved in the Summary of Product Characteristics. Physical urticaria, when manifesting isolatedly, tends to respond well to H1 antihistamines, with the exception of genuine solar urticaria and delayed pressure urticaria. In some cases of chronic urticaria, the combination of H2 antihistamines may prove effective--though only with common liver metabolism (CYP3A4 isoenzyme-mediated) H1 antihistamines, due to the existence of mutual metabolic interferences. The role of leukotriene antagonists associated to antihistamines in application to chronic urticaria remains to be clearly defined.
 ...
PMID:Antihistamines in the treatment of chronic urticaria. 1822 82

Physical urticaria is a rare but challenging subset of chronic urticaria. Wheals of pressure urticaria are typically delayed in appearance. A pressure test can easily be done to confirm the diagnosis.
 ...
PMID:Under pressure. 2296 37

Physical urticaria is often challenging to diagnose and manage. We present a case of both cholinergic and cold-induced urticaria and discuss the diagnosis and management strategies of these two important conditions.
 ...
PMID:The association of cholinergic and cold-induced urticaria: diagnosis and management. 2569 28

An instrument named Dermographism-Testing-and-Grading device was used for grading the response of patients having demographic urticaria, in comparison with controls. This device is capable of stroking the skin with, four different grades of pressure. The pressures used were such that none of the 250 controls (including.50 normal suliects, 100 patients having non-allergic skin diseases, 50 patients having non-urticarial allergic diseases and 50 patients having non-demographic urticaria), showed demographist with even the maximum pressure employed, while all the 25 patient, having demographic urticaria developed dermographism. Depending upon the minimum pressure re4uired, to elicit dermographism in these patients the severity of dermoloaphism could be graded as grade I in 8 patients, grade.11 in 6 and grade IV in 11 patients. None of the patients in " group showed grade III dermograph.ism. The dermographic grade varied at different body sites and local applications of oil, talcum powder and even tap water lowered the dermographic grade.
 ...
PMID:Grading the Response in Dermographic Urticaria. 2816 72

Symptomatic dermographism (SD) is the most common form of physical urticaria. So far no promising serum biomarkers for SD have been reported. Recently, microRNAs (miRNAs) have been reported to be serum biomarkers for chronic spontaneous urticaria. However, association of miRNAs with SD remains unclear. We enrolled 55 SD patients and 52 healthy controls in this study. We found that serum expressions of miR-126-3p and miR-16-5p were significantly downregulated in active SD patients and upregulated in remission. The area under the curve values of miR-126-3p (0.769) and miR-16-5p (0.789) showed significant ability to diagnostic SD. Serum level of vascular endothelial growth factor (VEGF)-A, a known target of the two miRNAs, was significantly increased in active SD patients and decreased in remission. Moreover, serum VEGF-A level was inversely correlated with expressions of miR-126-3p and miR-16-5p. Our findings indicate that miR-126-3p and miR-16-5p can serve as potential serum biomarkers for SD.
 ...
PMID:miR-126-3p and miR-16-5p as novel serum biomarkers for disease activity and treatment response in symptomatic dermographism. 3326 23


<< Previous 1 2